PharmaCyte Biotech (PMCB) executive compensation, 2026 proxy

Joshua N. Silverman, Chief Executive Officer and President, was paid $520,257 in 2025, down 37% from $829,585 the year before.

Filed
March 9, 2026
Annual meeting
March 30, 2026
Pay year
2025
Named executives
2
CEO total pay
$520,257-37% vs prior year
CEO Base Salary
$375,000Unchanged from prior year
CFO Base Salary
$380,000Unchanged from prior year
CEO Bonus
$100,000Annual bonus awarded
CFO Bonus
$50,000Annual bonus awarded
Target Equity Award
300%Percentage of CEO base salary

How Silverman was paid

$520,257 in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary72%Bonus19%All other compensation9%

Named executive officers

ExecutiveTotal
Joshua N. SilvermanChief Executive Officer and President$520,257
Carlos A. TrujilloChief Financial Officer$482,017

What changed and why

  • $520KCEO total compensation decreased to $520,257 in fiscal 2025 from $829,585 in fiscal 2024.
  • Neither executive received stock or option awards in fiscal 2025 compared to previous option grants.
  • $375KBase salary for the CEO remained flat at $375,000 during fiscal 2025.
  • $100KBonuses for the CEO and CFO remained steady at $100,000 and $50,000 respectively.
  • $45,257All other compensation for the CEO increased slightly to $45,257 primarily for health insurance.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.